← All trials
NCT01281475
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2011
- Primary completion
- Jul 1, 2015
- Completion date
- Jul 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 67
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- University of California, San DiegoCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San DiegoOverall official - principal investigator
- Greenwood Genetic CenterOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
- University of California, San FranciscoCollaborator
- Vanderbilt UniversityCollaborator
- University of CincinnatiCollaborator
- Greenwood Genetic CenterCollaborator
- Angelman Syndrome Foundation, Inc.Collaborator
- Baylor UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.